
Phathom Pharmaceuticals (PHAT) Stock Forecast & Price Target
Phathom Pharmaceuticals (PHAT) Analyst Ratings
Bulls say
Phathom Pharmaceuticals is attractive because VOQUEZNA is the first and only approved U.S. P-CAB, giving it a differentiated position in a large GERD market where roughly 110 million PPI prescriptions are filled annually and about 40% of patients may be PPI-inadequate responders. Its clinical profile is compelling, with rapid, durable acid suppression, 93% healing versus 85% for lansoprazole in erosive esophagitis, and improving real-world adoption as access frictions ease through targeted GI selling and BlinkRx support. Fundamentally, the setup also offers upside from a potential 2027 tegoprazan launch, Phase 2 EoE expansion, and exclusivity through 2032, while revenue is guided to $310–325 million in 2026 and EBITDA profitability is expected that year.
Bears say
Phathom Pharmaceuticals is facing a tougher-than-expected commercial ramp for VOQUEZNA, as physician access friction has slowed GERD prescribing and pushed out the expected reacceleration in 2026, which could reduce peak sales expectations. Competitive pressure is also building from Sebela’s tegoprazan, submitted on January 9, 2026 with anticipated US approval in January 2027, and its Phase 3 data across more than 2,000 patients showed superiority versus lansoprazole that could pressure Phathom’s share and pricing. Financially, the $300MM Hercules term loan is secured by nearly all assets, requires minimum cash of 20% of principal, and could force costly renegotiation or acceleration if covenants are missed.
This aggregate rating is based on analysts' research of Phathom Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Phathom Pharmaceuticals (PHAT) Analyst Forecast & Price Prediction
Start investing in Phathom Pharmaceuticals (PHAT)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Phathom Pharmaceuticals (PHAT) Forecast
Phathom Pharmaceuticals (PHAT) Analyst Forecast & Price Prediction
Start investing in Phathom Pharmaceuticals (PHAT)
Order type
Buy in
Order amount
Est. shares
0 shares